Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Apatinib vs Bevacizumab in 2nd-line mCRC
NCT03743428Suspended
- Sponsor
- Shenzhen People's Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Rivoceranib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Identify biomarkers specific to apatinib or bevacizumab by transcriptome analysis at 4 years and Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis at 4 years. Started Oct 2020; status: suspended.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03743428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743428.